Introduction_NN
#_SYM
This_DEMO
review_NN
addresses_VPRT
established_VBN
and_CC
emerging_VBG
glycan_NN
biomarkers_NN NCOMP
for_IN
detection_NN
,_,
prognosis_NN
and_CC
novel_JJAT
therapeutic_JJAT
strategies_NN
against_IN
gastric_JJAT
and_CC
colorectal_JJAT
carcinomas_NN
._.
These_DEMO
are_VPRT BEMA
among_IN
the_DT
most_EMPH
prevalent_JJAT
and_CC
deadliest_JJAT
gastrointestinal_JJAT
tract_NN
malignancies_NN NCOMP
in_IN
western_JJAT
populations_NN
1_CD
,_,
mostly_RB
due_IN
to_IN
late_JJAT
diagnosis_NN
,_,
rapid_JJAT
metastatic_JJAT
spread_NN
and_CC
scarce_JJAT
efficient_JJAT
therapeutics_NN
2_CD
-_SYM
4_CD
._.
In_IN
fact_NN ELAB
,_,
current_JJAT
treatments_NN
rely_VPRT
essentially_RB
on_IN
surgery_NN
associated_VBN
with_IN
(_-LRB-
neo_NN
)_-RRB-
adjuvant_NN
chemotherapy_NN NCOMP
,_,
which_WHSC
is_VPRT BEMA
highly_AMP
toxic_JJPR
and_CC
provides_VPRT
only_DWNT
modest_JJAT
results_NN
for_IN
advanced_JJAT
stage_NN
patients_NN NCOMP
2,5_CD
-_SYM
7_CD
._.
Over_IN
the_DT
past_JJAT
ten_CD
years_NN
the_DT
introduction_NN
of_IN
targeted_VBN
therapeutics_NN
and_CC
immunotherapy_NN
has_VPRT
allowed_PEAS
significant_JJPR
,_,
but_CC
yet_CC
insufficient_JJPR
,_,
improvements_NN
in_IN
disease_NN
management_NN NCOMP
8_CD
-_SYM
10_CD
._.
As_IN
the_DT
oncology_JJAT
field_NN
moves_VPRT
toward_IN
precision_NN
medicine_NN NCOMP
and_CC
patient_JJPR
-_HYPH
tailored_VBN
therapeutic_JJAT
solutions_NN
,_,
it_PIT
becomes_VPRT
imperative_JJPR
to_IN
accomplish_VB
a_DT
more_EMPH
integrative_JJPR
and_CC
in_IN
-_HYPH
depth_NN
overview_NN NCOMP
of_IN
the_DT
molecular_NN
nature_NN NCOMP
of_IN
tumors_NN
11_CD
-_SYM
13_CD
._.
#_SYM
Alterations_NN
in_IN
protein_NN
glycosylation_NN NCOMP
are_VPRT BEMA
among_IN
the_DT
main_JJAT
molecular_NN
events_NN NCOMP
accompanying_VBG
oncogenic_JJAT
transformations_NN
in_IN
the_DT
gastric_NN
and_CC
colorectal_JJAT
tracts_NN
14_CD
-_SYM
16_CD
._.
In_IN
fact_NN ELAB
,_,
protein_NN
glycosylation_NN NCOMP
is_VPRT BEMA
one_CD
of_IN
the_DT
most_EMPH
frequent_JJPR
,_,
complex_JJAT
and_CC
plastic_JJAT
posttranslational_JJAT
modifications_NN
of_IN
membrane_NN
-_HYPH
bound_JJPR
and_CC
secreted_VBN
proteins_NN
17_CD
._.
Glycans_NN
play_VPRT
a_DT
key_JJAT
role_NN
in_IN
protein_NN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
several_QUAN
cell_NN
functions_NN NCOMP
,_,
such_JJPR
as_IN ELAB
cell_NN
adhesion_NN NCOMP
,_,
migration_NN
and_CC
signaling_NN
,_,
as_CC
well_RB
as_IN
modulate_VB
immune_JJAT
recognition_NN
and_CC
host_NN
-_HYPH
pathogen_NN
interactions_NN NCOMP
16,18_CD
-_SYM
20_CD
._.
Protein_NN
glycosylation_NN NCOMP
results_NN
from_IN
the_DT
highly_AMP
coordinated_VBN
action_NN
of_IN
nucleotide_JJAT
sugar_NN
transporters_NN NCOMP
and_CC
sugar_NN
biosynthesis_NN NCOMP
pathways_NN
,_,
involving_VBG
glycosyltransferases_NN
(_-LRB-
GTs_NN
)_-RRB-
and_CC
glycosidases_NN
in_IN
the_DT
endoplasmatic_JJAT
reticulum_NN
and_CC
the_DT
Golgi_NN
apparatus_NN NCOMP
._.
As_IN
such_JJPR
,_,
several_QUAN
factors_NN
may_MDMM
influence_VB
glycan_NN
biosynthesis_NN NCOMP
,_,
namely_ELAB
,_,
the_DT
under_NN
or_CC
overexpression_NN
of_IN
glycosyltransferases_NN
,_,
the_DT
impairment_NN
of_IN
glycosyltransferase_NN
chaperone_NN NCOMP
function_NN
,_,
altered_VBN
glycosidase_NN
activity_NN NCOMP
,_,
changes_NN
in_IN
the_DT
tertiary_JJAT
conformation_NN
of_IN
a_DT
given_VBN
peptide_NN
or_CC
growing_VBG
glycan_NN
,_,
and_CC
the_DT
availability_NN
of_IN
sugar_NN
nucleotide_NN NCOMP
donors_NN
,_,
cofactors_NN
and_CC
acceptor_NN
substrates_NN NCOMP
21,22_CD
._.
The_DT
mislocalization_NN
of_IN
glycosyltranferases_NN
throughout_IN
the_DT
secreting_VBG
organelles_NN
also_CC
contributes_VPRT
to_IN
significant_JJAT
alterations_NN
in_IN
cancer_NN
-_HYPH
associated_VBN
protein_NN
glycosylation_NN NCOMP
patterns_NN
23_CD
-_SYM
25_CD
._.
Two_CD
main_JJAT
classes_NN
of_IN
glycans_NN
can_MDCA
be_VB
found_PASS
at_IN
cell_NN
-_HYPH
surface_NN
glycoproteins_NN NCOMP
:_:
i_PP1S
)_-RRB-
O_NN
-_HYPH
glycans_NN
,_,
being_VBG BEMA
the_DT
most_EMPH
common_JJAT
O_NN
-_HYPH
glycan_NN
that_THRC
is_VPRT
initiated_PASS
in_IN
the_DT
Golgi_NN
by_IN
the_DT
attachment_NN
of_IN
a_DT
GalNAc_NN
residue_NN NCOMP
to_IN
the_DT
hydroxyl_NN
groups_NN NCOMP
of_IN
serine_NN
(_-LRB-
Ser_NN
)_-RRB-
or_CC
threonine_NN
(_-LRB-
Thr_NN
)_-RRB-
amino_NN
acids_NN NCOMP
of_IN
a_DT
given_VBN
polypeptide_NN
chain_NN NCOMP
(_-LRB-
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
O_NN
-_HYPH
glycosylation_NN
)_-RRB-
26_CD
;_:
and_CC
ii_FPUH
)_-RRB-
N_FW
-_HYPH
glycans_NN
,_,
whose_WHSC
biosynthesis_NN
initiates_VPRT
in_IN
the_DT
endoplasmatic_JJAT
reticulum_NN
by_IN
the_DT
addition_NN
of_IN
an_DT
oligosaccharide_JJAT
chain_NN
to_IN
an_DT
asparagine_NN
(_-LRB-
Asn_NN
)_-RRB-
residue_NN
within_IN
consensus_NN
peptide_NN NCOMP
sequences_NN
of_IN
Asn_NN
-_HYPH
X_NN
-_HYPH
Ser_NN
/_SYM
Thr_NN
(_-LRB-
X_NN
denotes_VPRT
any_QUAN
amino_NN
acid_NN NCOMP
except_IN
proline_NN
)_-RRB-
27_CD
._.
Less_RB
abundant_JJAT
forms_NN
of_IN
protein_NN
glycosylation_NN NCOMP
include_VPRT
O_NN
-_HYPH
Fucosylation_NN
,_,
O_NN
-_HYPH
GlucNAcylation_NN
,_,
and_CC
O_NN
-_HYPH
Mannosylation_NN
16_CD
._.
Protein_NN
glycan_NN NCOMP
chains_NN
are_VPRT SPLIT
often_FREQ
branched_PASS
or_CC
elongated_PASS
and_CC
may_MDMM
present_VB
sialic_NN
acids_NN NCOMP
,_,
Lewis_NN
blood_NN NCOMP
group_NN
related_JJAT
antigens_NN
or_CC
ABO_NN
(_-LRB-
H_NN
)_-RRB-
blood_NN
group_NN NCOMP
determinants_NN
as_IN
terminal_JJAT
structures_NN
28_CD
._.
Other_JJAT
modifications_NN
may_MDMM
include_VB
phosphorylation_NN
,_,
O-acetylation_NN
of_IN
sialic_NN
acids_NN NCOMP
and_CC
O_NN
-_HYPH
sulfation_NN
of_IN
galactose_NN
and_CC
N_NN
-_HYPH
acetylglucosamine_NN
residues_NN NCOMP
,_,
thereby_CC
increasing_VBG
the_DT
structural_JJAT
complexity_NN
of_IN
the_DT
glycophenotype_NN
29_CD
._.
In_IN
addition_NN CC
,_,
protein_NN
glycosylation_NN NCOMP
patterns_NN
do_VPRT DOAUX
not_XX0
follow_VB
a_DT
predefined_VBN
template_NN
,_,
as_IN
they_PP3t
are_VPRT
regulated_PASS
by_IN
several_QUAN
factors_NN
at_IN
the_DT
cell_NN
and_CC
tissue_NN
levels_NN NCOMP
,_,
promptly_RB
responding_VBG
to_IN
physiological_JJAT
and_CC
pathological_JJAT
changes_NN
16_CD
._.
#_SYM
Given_VBN
its_PIT
key_JJAT
functional_JJAT
and_CC
biological_JJAT
role_NN
,_,
alterations_NN
in_IN
protein_NN
glycosylation_NN NCOMP
underlying_VBG
oncogenic_JJAT
transformations_NN
decisively_RB
contribute_VPRT
to_IN
the_DT
development_NN
of_IN
more_EMPH
malignant_JJAT
characteristics_NN
,_,
such_JJPR
as_IN ELAB
cell_NN
-_HYPH
cell_NN
adhesion_NN NCOMP
impairment_NN
,_,
enhanced_VBN
migration_NN
and_CC
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
been_VBN SPLIT
also_CC
implicated_PASS
in_IN
the_DT
activation_NN
of_IN
intracellular_JJAT
oncogenic_JJAT
pathways_NN
and_CC
immune_JJAT
escape_NN
,_,
thereby_CC
favoring_VBG
cancer_NN
-_HYPH
tolerogenic_JJAT
immune_JJAT
responses_NN
33,34_CD
._.
Particularly_RB
,_,
advanced_JJAT
stage_NN
tumors_NN NCOMP
often_FREQ
overexpress_VPRT
or_CC
promote_VPRT
the_DT
de_FW
novo_NN
biosynthesis_NN NCOMP
of_IN
immature_JJPR
and_CC
truncated_VBN
O_NN
-_HYPH
glycans_NN
,_,
such_JJPR
as_IN ELAB
the_DT
Tn_NN
,_,
sialyl_RB
-_HYPH
Tn_NN
(_-LRB-
STn_NN
)_-RRB-
,_,
T_NN
and_CC
sialyl_NN
-_HYPH
T_NN
(_-LRB-
ST_NN
)_-RRB-
antigens_NN
,_,
due_IN
to_IN
a_DT
premature_JJAT
stop_NN
of_IN
the_DT
extension_NN
of_IN
O_NN
-_HYPH
glycosylation_NN
35_CD
-_SYM
37_CD
._.
Oversialylation_RB
and_CC
fucosylation_NN
of_IN
glycan_NN
chains_NN NCOMP
are_VPRT SPLIT
also_CC
frequently_FREQ
observed_VBN
in_IN
cancer_NN
,_,
including_VBG
terminal_JJAT
antigens_NN
like_LIKE
the_DT
sialyl_RB
-_HYPH
LeA_NN
(_-LRB-
SLeA_NN
)_-RRB-
and_CC
sialyl_RB
-_HYPH
LeX_NN
(_-LRB-
SLeX_NN
)_-RRB-
38_CD
-_SYM
40_CD
._.
Contrasting_VBG
with_IN
the_DT
tumor_NN
,_,
these_DEMO
structures_NN
are_VPRT BEMA
often_FREQ
absent_JJPR
or_CC
just_EMPH
moderately_RB
expressed_VBN
in_IN
the_DT
corresponding_VBG
healthy_JJAT
tissues_NN
,_,
holding_VBG
potential_NN
for_IN
selective_JJPR
targeted_VBN
therapeutics_NN
38_CD
._.
In_IN
addition_NN CC
,_,
many_QUAN
of_IN
the_DT
proteins_NN
carrying_VBG
cancer_NN
-_HYPH
associated_VBN
glycans_NN
may_MDMM SPLIT
also_CC
be_VB BEMA
she_PP3f
'd_VBD CONT
into_IN
the_DT
bloodstream_NN
or_CC
other_JJAT
bodily_JJAT
fluids_NN
,_,
facilitating_VBG
non-invasive_JJAT
detection_NN
methods_NN NCOMP
._.
#_SYM
Despite_CONC
the_DT
key_JJAT
role_NN
played_VBN
by_IN
glycosylation_NN
,_,
clinically_RB
approved_VBN
and_CC
novel_JJPR
targeted_VBN
therapeutic_JJAT
approaches_NN
for_IN
gastric_JJAT
and_CC
colorectal_JJAT
tumors_NN
have_VPRT SPLIT
mostly_RB
resulted_PEAS
from_IN
intense_JJAT
genomic_JJPR
,_,
transcriptomic_JJAT
and_CC
proteomic_JJAT
studies_NN
._.
Moreover_CC
,_,
few_QUAN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
of_IN
gastric_JJAT
and_CC
colorectal_JJAT
tumors_NN
,_,
mostly_RB
due_IN
to_IN
its_PIT
intrinsic_JJAT
molecular_NN
complexity_NN NCOMP
._.
This_DEMO
has_VPRT SPLIT
significantly_RB
delayed_PEAS
the_DT
development_NN
and_CC
translation_NN
of_IN
glycan_NN
-_HYPH
based_VBN
diagnostic_JJAT
and_CC
therapeutic_JJAT
solutions_NN
to_IN
clinical_JJAT
routine_NN
._.
Recently_TIME
,_,
the_DT
simplification_NN
and_CC
standardization_NN
of_IN
glycobiology_NN
-_HYPH
based_VBN
methods_NN
have_VPRT
provided_PEAS
powerful_JJAT
analytical_JJAT
tools_NN
to_IN
improve_VB
our_PP1P
understanding_NN
of_IN
glycosylation_NN
alterations_NN NCOMP
on_IN
specific_JJAT
cancer_NN
-_HYPH
associated_VBN
proteins_NN
._.
This_DEMO
review_NN
summarizes_VPRT
recent_JJAT
insights_NN
from_IN
innovative_JJAT
research_NN
on_IN
the_DT
glycobiology_NN
of_IN
gastric_JJAT
and_CC
colorectal_JJAT
tumors_NN
._.
It_PIT
emphasizes_VPRT
the_DT
O_NN
-_HYPH
glycome_NN
and_CC
glycoproteome_NN
,_,
envisaging_VBG
the_DT
identification_NN
of_IN
more_EMPH
specific_JJAT
cancer_NN
glycobiomakers_NN NCOMP
and_CC
the_DT
development_NN
of_IN
innovative_JJAT
therapeutic_JJAT
strategies_NN
._.
Furthermore_CC
,_,
it_PIT
comprehensively_RB
discusses_VPRT
the_DT
implications_NN
of_IN
combining_VBG
glycosylation_NN
,_,
large_JJAT
scale_NN
genomics_NN NCOMP
,_,
transcriptomics_NN
and_CC
metabolomics_NN
toward_IN
true_JJAT
precision_NN
medicine_NN NCOMP
settings_NN
._.
#_SYM
Protein_NN
glycosylation_NN NCOMP
in_IN
gastrointestinal_JJAT
cancer_NN
:_:
molecular_NN
mechanisms_NN NCOMP
underlying_VBG
the_DT
aberrant_JJAT
glycan_NN
biosynthesis_NN NCOMP
#_SYM
Perhaps_HDG
the_DT
most_EMPH
studied_VBN
cancer_NN
-_HYPH
associated_VBN
glycoepitopes_NN
in_IN
gastric_JJAT
and_CC
colorectal_JJAT
cancers_NN
derive_VPRT
from_IN
a_DT
premature_JJAT
stop_NN
in_IN
the_DT
elongation_NN
of_IN
protein_NN
O_IN
-_HYPH
GalNAc_NN
glycosylation_NN NCOMP
16,37,41_CD
._.
These_DEMO
antigens_NN
have_VPRT
been_PEAS SPLIT
classically_RB
termed_PASS
as_IN
simple_JJAT
mucin_NN
-_HYPH
type_NN
O_NN
-_HYPH
glycans_NN
,_,
reflecting_VBG
the_DT
abundance_NN
of_IN
this_DEMO
type_NN
of_IN
glycosylation_NN
in_IN
mucins_NN
._.
Nevertheless_CONC
,_,
these_DEMO
types_NN
of_IN
glycans_NN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
@_IN
protein_NN
expressing_VBG
O_IN
-_HYPH
glycosylation_NN
sites_NN NCOMP
._.
O_NN
-_HYPH
GalNAc_NN
glycan_NN NCOMP
biosynthesis_NN
can_MDCA
be_VB
initiated_PASS
by_IN
up_RP
to_IN
20_CD
polypeptide_NN
GalNAc_NN
transferases_NN NCOMP
(_-LRB-
GalNAc_NN
-_HYPH
Ts_NN
)_-RRB-
,_,
which_WHSC
are_VPRT BEMA
responsible_JJPR
for_IN
catalyzing_VBG
the_DT
transfer_NN
of_IN
a_DT
N_FW
-_HYPH
acetylgalactosamine_JJAT
residue_NN
from_IN
UDP_NN
-_HYPH
GalNAc_NN
to_IN
the_DT
hydroxyl_NN
group_NN NCOMP
of_IN
Ser_NN
or_CC
Thr_NN
,_,
originating_VBG
the_DT
Tn_NN
antigen_NN NCOMP
(_-LRB-
Fig._NN
1_CD
)_-RRB-
42_CD
-_SYM
44_CD
._.
The_DT
different_JJAT
GalNAcTs_NN
present_VPRT
a_DT
cell_NN
and_CC
tissue_NN
-_HYPH
specific_JJAT
expression_NN
45_CD
,_,
showing_VBG
distinct_JJPR
and_CC
partially_DWNT
overlapping_VBG
peptide_NN
substrate_NN NCOMP
specificities_NN
that_THRC
are_VPRT BEMA
crucial_JJPR
for_IN
O_NN
-_HYPH
glycosites_NN
definition_NN NCOMP
46_CD
._.
There_EX
have_VPRT
been_PEAS
reports_NN
of_IN
an_DT
increased_VBN
density_NN
of_IN
O_NN
-_HYPH
glycans_NN
in_IN
gastric_NN
and_CC
colon_NN
tumors_NN NCOMP
,_,
resulting_VBG
from_IN
an_DT
increased_VBN
GalNAc_NN
-_HYPH
Ts_NN
activity_NN NCOMP
in_IN
tumor_NN
cells_NN NCOMP
compared_VBN
to_IN
normal_JJAT
cells_NN
20,47_CD
._.
In_IN
most_EMPH
normal_JJAT
gastrointestinal_JJAT
cells_NN
,_,
the_DT
Tn_NN
antigen_NN NCOMP
is_VPRT SPLIT
further_CC
elongated_PASS
by_IN
core_NN
1_CD
**25;17515;TOOLONG_CD
(_-LRB-
C1GalT_NN
)_-RRB-
._.
This_DEMO
reaction_NN
originates_VPRT
the_DT
core_NN
1_CD
or_CC
Thomsen_NN
-_HYPH
Friedenreich_NN
(_-LRB-
T_NN
)_-RRB-
-_HYPH
antigen_NN
(_-LRB-
Gal1_NN
-_HYPH
3GalNAc_NN
-_HYPH
Ser_NN
/_SYM
Thr_NN
)_-RRB-
,_,
in_IN
a_DT
process_NN
dependent_JJPR
on_IN
the_DT
functional_JJAT
chaperone_NN
COSMC_NN
(_-LRB-
Fig._NN
1_CD
)_-RRB-
48_CD
._.
The_DT
initial_JJAT
GalNAc_NN
may_MDMM
be_VB
extended_PASS
and_CC
originate_VB
the_DT
core_NN
3_CD
,_,
catalyzed_VBN
by_IN
**36;17542;TOOLONG_CD
6_CD
(_-LRB-
3_CD
Gn_NN
-_SYM
T6_NN
)_-RRB-
._.